Amicus Therapeutics (Nasdaq: FOLD) announced that it has now achieved target enrollment and has 56 patients in its second Phase ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE